To provide a novel oligomeric compound in the field of oligonucleotide therapeutics, and specifically for enhancing properties of the oligonucleotides.SOLUTION : The invention provides an oligomeric compound of 8-35 nucleotides in length, comprising three regions : i) a first region (region A) comprising 7-26 contiguous nucleotides; ii) a second region (region B) which comprises 1-10 nucleotides, and is covalently linked to the 5' or 3' nucleotide of the first region, e.g., via an internucleoside linkage group such as a phosphodiester linkage; and iii) a third region which comprises a conjugate moiety, targeting moiety, reactive group or blocking moiety, and is covalently linked to the second region.SELECTED DRAWING : Figure 3